{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T19:27:02Z","timestamp":1748978822177},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5,5]]},"DOI":"10.4103\/0366-6999.230742","type":"journal-article","created":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T05:21:26Z","timestamp":1524201686000},"page":"1009-1012","source":"Crossref","is-referenced-by-count":2,"title":["Biologic Targeting"],"prefix":"10.1097","volume":"131","author":[{"given":"Xin","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Rong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song-Min","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210129","doi-asserted-by":"crossref","first-page":"879783","DOI":"10.1155\/2015\/879783","article-title":"Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma","volume":"2015","author":"Pelaia","year":"2015","journal-title":"Mediators Inflamm"},{"key":"R2-1-20210129","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","article-title":"The prevalence of severe refractory asthma","volume":"135","author":"Hekking","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"R3-1-20210129","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1172\/JCI36130","article-title":"The cytokine network in asthma and chronic obstructive pulmonary disease","volume":"118","author":"Barnes","year":"2008","journal-title":"J Clin Invest"},{"key":"R4-1-20210129","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1164\/rccm.201611-2234OC","article-title":"Mepolizumab attenuates airway eosinophil numbers, but not their functional phenotype, in asthma","volume":"196","author":"Kelly","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"R5-1-20210129","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1164\/rccm.201707-1323OC","article-title":"Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab","volume":"197","author":"Mukherjee","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"R6-1-20210129","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"R7-1-20210129","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"R9-1-20210129","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.0105-2896.2004.00215.x","article-title":"Interleukin-13 in asthma pathogenesis","volume":"202","author":"Wills-Karp","year":"2004","journal-title":"Immunol Rev"},{"key":"R10-1-20210129","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1183\/09031936.00223411","article-title":"A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma","volume":"41","author":"Piper","year":"2013","journal-title":"Eur Respir J"},{"key":"R11-1-20210129","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMoa1106469","article-title":"Lebrikizumab treatment in adults with asthma","volume":"365","author":"Corren","year":"2011","journal-title":"N Engl J Med"},{"key":"R12-1-20210129","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2147\/TCRM.S125964","article-title":"Dupilumab in the management of moderate-to-severe asthma: The data so far","volume":"13","author":"Barranco","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"R13-1-20210129","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1465-9921-11-78","article-title":"Interleukin-17 regulation: An attractive therapeutic approach for asthma","volume":"11","author":"Park","year":"2010","journal-title":"Respir Res"},{"key":"R14-1-20210129","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: A randomised, double-blind, placebo-controlled trial","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet"},{"key":"R15-1-20210129","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/leu.2015.228","article-title":"Targeting IL-17A in multiple myeloma: A potential novel therapeutic approach in myeloma","volume":"30","author":"Prabhala","year":"2016","journal-title":"Leukemia"},{"key":"R16-1-20210129","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1183\/09031936.00123612","article-title":"The anti-IL-17A antibody secukinumab does not attenuate ozone-induced airway neutrophilia in healthy volunteers","volume":"41","author":"Kirsten","year":"2013","journal-title":"Eur Respir J"},{"key":"R17-1-20210129","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1164\/rccm.201212-2318OC","article-title":"Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma","volume":"188","author":"Busse","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"R18-1-20210129","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"key":"R19-1-20210129","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaci.2016.11.027","article-title":"Bcl-2 inhibitors reduce steroid-insensitive airway inflammation","volume":"140","author":"Tian","year":"2017","journal-title":"J Allergy Clin Immunol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/0366-6999.230742","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T19:47:24Z","timestamp":1623959244000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00029330-201805050-00001"}},"subtitle":["New and Effective Therapeutic Approaches against Severe Asthma"],"short-title":[],"issued":{"date-parts":[[2018,5,5]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.4103\/0366-6999.230742","relation":{},"ISSN":["0366-6999"],"issn-type":[{"value":"0366-6999","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5,5]]}}}